Aps Type 1 Foundation

Nonprofit profile at a glance

EIN
320241819
IRS 990-EZ coverage
2016–2025
Forms available
Form 990-EZ 2025, Form 990-N 2018
Location
Stony Brook, NY, USA
Phone
6316825550
Rating
46
Verdict
MIXED
Rating confidence
Moderate
Sector
Specifically Named Diseases

Official website

Reported finances

Revenue
$126,409
Expenses
$112,896
Assets
$372,552
Liabilities
$0

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

9 people listed

Executive titles in this filing

  • Todd Talarico (President)
  • Jennifer Orange (Vice President)

People named in this filing

  • Sherri Seyfert (Treasurer)
  • Todd Talarico (President)
  • Jennifer Orange (Vice President)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

The APS Type 1 Foundation unites and empowers a global community to drive awareness, education, and groundbreaking research for APS Type 1, transforming lives affected by this autoimmune disorder.

What it reported doing in 2025

The APS Type 1 Foundation's community is approximately 200 in North America and counting. There are many undiagnosed APS Type 1 patients throughout the United States and worldwide. The Foundations has assisted in decreasing the time to diagnosis; on average, it was 7-10 years when we started, and it can now take 4-5 years. The Foundation's accomplishments for 2024 include Education: This July, The APS Type 1 Foundation Inc. held its 6th Biannual International Symposium on APS Type 1 in San Francisco, California. This symposium provides much-needed education, especially for the newly diagnosed patients, their families, physicians, and clinicians worldwide. We are helping to promote best practices and increase research interest throughout the world. Awareness: The Foundation held our second Global Summit in San Francisco in July 2024. This event is for physicians and research scientists. For this event, the Foundation partnered with the Clinical Immunology Society and the National Institute of Allergy and Infectious Diseases. We are hoping to hold our third in 2026. We continue awareness and education through our website, quarterly newsletters and on social media platforms. Research: The Foundation continues to fund research in APS Type 1, also known as APECED, typically every two years. We continue to run the first-ever Natural History Registry on APS Type 1.

Operating model

Revenue model
Donor-supported. 100% of the money available for current operations came from contributions and gifts.
Distribution model
No current program activity. The filing reports no program spending for the current year.

The verdict

MIXED - The filed numbers largely add up and total assets are large relative to annual expenses, but may not be spendable cash. A relatively small share of available resources goes toward mission work and a relatively small share of total spending goes to programs.

Rating breakdown

  • Financial Efficiency: 0
  • Transparency & Controls: 100
  • Sustainability: 69
  • Growth: 60

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 0%; rating input score 0
  • Program expense ratio: 0%; rating input score 0

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 52nd percentile among comparable filings
  • Major donor itemization: Yes; rating input score 100

Sustainability

  • Operating margin: 10.7%; rating input score 57; 57th percentile among comparable filings
  • Total-asset coverage ratio: 3.3; rating input score 90; 90th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 74; 74th percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 63; 63rd percentile among comparable filings

Growth

  • Program expense growth: -33.8% per year; rating input score 0; 7th percentile among comparable filings
  • Revenue growth: 2% per year; rating input score 100; 28th percentile among comparable filings
  • Asset growth: 11% per year; rating input score 100; 62nd percentile among comparable filings

Details

  • Where the money goes: 0% of revenue deployed · 0% of spending went to programs
  • Governance: Filed governance answers
  • Accomplishments: 1 filed program accomplishment
  • Leadership: top reported pay $0 · 9 people listed
  • Consistency: 9 of 9 current checks pass
  • Schedules: 3 filed schedules
  • Filing history: 9 filing years from 2016 to 2025
  • Contacts: How to reach this organization
  • Money network: Resolved incoming and outgoing counterparties from filed money flows.
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Financial Efficiency: Mission deployment rate scored 0/100.
  • High — Financial Efficiency: Program expense ratio scored 0/100.
  • High — Growth: Program expense growth scored 0/100.
  • Review — Sustainability: Operating margin scored 57/100.